In partnership with
Explore the World of Plant Medicine and Psychedelics. A Weekly Digest of Exclusive Stories, Insights, and Research.
Welcome to this week’s edition of The Guide ⚡
Today’s newsletter takes about 5 minutes to read—so if you’ve only got 60 seconds, here’s what you need to know:
Anorexia nervosa is still one of the most dangerous mental health conditions. Recent research puts mortality at ~5x higher than the general population…
Psilocybin is being/has been explored as a potential treatment for anorexia. Early research has looked at whether psychedelic-assisted therapy could help shift rigid thought patterns and body-image distress that often make the disorder so difficult to treat…
The early findings are encouraging, but the research is still in its early stages. Larger, controlled studies are needed before scientists can determine how effective this approach might be or how it could fit into future treatment options…
🎙️ This week on the pod: Scott sits down with Colette Condorcita Schmitt to debunk myths about shamanism to give insights about what it is, what it isn’t, and how to approach it with respect.
👉 We’ve personally seen the dire effects that eating disorders can have on a person’s health, family, and friendships, so this one is near and dear to us…
We’ve got some interesting topics coming up over the next few weeks, so be sure to stick around for more!
🧠 The Webdelics Team
👋 New here? We do this every week… Join Us!
🎙️ Shamanism, Spirits, and Healing — with Colette Condorcita Schmitt
🎧 In this episode, Scott sat down with the founder of Neurodelics, Colette Condorcita Schmitt, to clear up the confusion around shamanism within the psychedelic space.
Colette gives insights about what it is (and what it isn’t), whether it involves spirits or “energies,” and why so many people are newly curious about this path…
🪶 She also shares her personal journey and the healing she’s witnessed across different phases of life, dispelling common myths and challenging modern assumptions about who can practice shamanism and how to approach it with respect.
Most anti-aging devices are expensive placebos. This one isn't.
Red light therapy sounds like wellness bullsh*t. We get it.
But Celluma is the only LED brand with 5 FDA clearances, not just for wrinkles, but also pain relief, hair growth, body contouring & more. Clinical trials showed 80% improvement in skin texture and a 66% reduction in wrinkles after 4 weeks of consistent use.
Most LED devices don't have the power density or wavelength precision to actually do anything. Celluma does. With proprietary processor-driven algorithms that deliver proven results, plus a patented design that shapes around your face, scalp, or any body part. No needles, no downtime, no Botox appointments.
The only catch? Consistent use. This isn't a one-and-done fix. It's mitochondrial support for your skin & entire body, a fancy way of saying it helps your cells do their job.
If you're already spending money on anti-aging stuff anyway, at least try something with actual clinical backing.
Results vary. Consistency required. FDA-cleared for specific indications.
📜 The “Must Read” For The Week
Could Psilocybin-Assisted Therapy Be the Next Breakthrough Treatment for Anorexia…?
Recent research suggests psilocybin-assisted therapy might offer new hope for individuals with anorexia nervosa, a life-threatening disorder characterized by severe food restriction and intense fear of weight gain.
In a 2023 phase 1, open-label feasibility study, 10 adult females diagnosed with anorexia nervosa (or partial remission) received a single 25 mg dose of synthetic psilocybin alongside psychological support…
Researchers monitored safety, tolerability, and how psilocybin might influence anorexia symptoms over three months.
And here’s what they found…
🥼 Safety and Tolerability
Overall, the treatment proved well-tolerated in this small sample. Reported adverse events were mild and transient, and no clinically significant changes were observed in ECG or vital signs, which is a big deal for a medically vulnerable population like this.
There were also no clinically significant increases in suicidality scores overall…Although one participant with a prior history reported increased suicidal ideation at 3 months post-treatment, the authors say it did not appear related to study participation.
Two participants briefly experienced asymptomatic low blood sugar (hypoglycemia) after treatment, but both instances resolved within 24 hours.
As a result, the research team treated this as an important safety sign and adjusted procedures (including food intake timing) to reduce risk for future events.
Given the medical complications often seen in anorexia nervosa, these early safety outcomes are quite impressive, and they’re exactly why newer safety-focused reviews emphasize AN-specific precautions in psychedelic protocols.
❤️🩹 Symptom Changes & Responses to Treatment
Overall, the study participants showed positive psychological shifts with psilocybin-assisted therapy.
Weight and body shape concerns both dropped significantly from baseline to the one-month follow-up, and at three months, weight concerns remained significantly lower overall.
Body shape concerns were still lower on average, but the change was less statistically robust, once again highlighting how variable response can be in small samples… Which is a great reason to conduct further studies.
Around 40% of participants had Eating Disorder Examination (EDE) scores that fell within one standard deviation of community norms by three months, suggesting clinically meaningful improvement for a subset of the group.
While changes in eating concerns and dietary restraint didn’t reach statistical significance, results suggested possible benefits that larger studies might capture more clearly.
BMI changes were inconsistent (psychological progress doesn’t always align immediately with weight restoration), though five participants did see increases in BMI over follow-up, which is a big deal for this vulnerable group.
🙏 Secondary Measures and Personal Impact
Beyond the core anorexia symptoms, participants reported decreases in anxiety, body image anxiety, and certain ritualistic eating behaviors one month after dosing, although these changes varied person to person…
More importantly, subjective experiences of the treatments were overwhelmingly positive:
90% felt more optimistic about life after psilocybin…
80% ranked the session among their top five most meaningful life events…
70% noted improvements in identity and quality of life. No one dropped out, suggesting strong engagement and increased perceived benefits of treatment…
🛣️ The Need for Future Studies
Although the study’s design had limitations (small sample size, no control group, etc.), it offers a promising glimpse of psilocybin’s potential in the treatment of anorexia nervosa and sets the stage for larger, controlled trials.
And since this publication, a 2025 systematic review mapped the current evidence and registered clinical trials, reinforcing the need for larger trials and placebo-controlled studies to confirm efficacy and refine treatment protocols.
As you can see, we’re still in the early stages of this quickly growing landscape…
And we will keep you posted on future studies!
👉 Subscribe to The Guide for evidence-based takes on psychedelics, research, and integration tools—delivered weekly to your inbox.
💬 Challenging Our Beliefs Isn’t Always Easy…
As James Baldwin once wrote, “Not everything that is faced can be changed, but nothing can be changed until it is faced.”
That’s the posture we need in the psychedelic space…
Where awe can blur into certainty, and certainty can outrun the data… But still remain in evidence and science-based reasoning.
🧠 If this week’s newsletter stimulated your cortex, here’s some recent news to know:
⚡️ Research: A Phase IIa trial of IV DMT (SPL026) paired with psychotherapeutic support reported rapid reductions in depression symptoms and a tolerable safety profile.
🏛️ Policy: State-level psychedelic policy proposals keep popping up, as Iowa is weighing regulated psilocybin access, Missouri is moving multiple psilocybin bills (including a veterans-focused model) and ibogaine trial legislation, and New Jersey has launched a $6M hospital-based psilocybin research pilot study program.
🕺 Culture: Everyone’s favorite psychedelic-advocate/author, Michael Pollan, is back at it again in a new Rolling Stone interview where he discusses psychedelics, consciousness, and why AI may warp how we think about the mind.
At Webdelics, we’re here to make plant-medicine and psychedelic education clear, evidence-based, and actionable, so you can make informed choices with fewer regrets…
📩 If this helped, forward it to someone who could use a good dose of love in their life…
💬 Questions, corrections, or topics to cover next? Hit reply.
🪧 Want to sponsor? [email protected]
🧠 The Guide - by Webdelics
Disclaimer: Webdelics does not support or promote any illegal activities, including the use of substances that may be mentioned in this newsletter. We encourage all readers to familiarize themselves with and adhere to the laws in their region. Please note that Webdelics does not offer mental health, medical, or clinical services and should not be used as a replacement for professional medical, psychological, or psychiatric care, diagnosis, or treatment.
